AbbVie IncStrong immunology launches Skyrizi and Rinvoq offset Humira's loss of exclusivity, plus expanding neuroscience portfolio.
Zacks Equity Research released new analyst reports on 16 major stocks, including Applied Materials, Mastercard, and AbbVie, along with micro-cap companies INNOVATE and BranchOut Food. Applied Materials benefits from AI-driven demand and record revenue, though faces China export rule risks. Mastercard sees steady payment network growth but rising expenses and geopolitical headwinds. AbbVie navigates Humira's loss of exclusivity with strong immunology launches Skyrizi and Rinvoq, while expanding its neuroscience portfolio. INNOVATE's investment case is anchored by DBMG's infrastructure exposure, but a highly leveraged balance sheet tempers the outlook. BranchOut Food shows improving revenue visibility through European private-label expansion and a strengthening retail pipeline.
AbbVie IncStrong immunology launches Skyrizi and Rinvoq offset Humira's loss of exclusivity, plus expanding neuroscience portfolio.
Applied Materials IncBenefits from AI-driven demand and record revenue, but faces China export rule risks.
Mastercard IncSteady payment network growth but rising expenses and geopolitical headwinds.
BranchOut Food Inc. Common StockImproving revenue visibility through European private-label expansion and strengthening retail pipeline.
Innovate CorpInvestment case anchored by DBMG's infrastructure exposure, but highly leveraged balance sheet tempers outlook.